Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-168 in relapsed or refractory B-cell malignancies
NCT04775745Phase 1Recruiting
- Sponsor
- Newave Pharmaceutical Inc.
- Start
- Jul 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rocbrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia (WM) and 5 more (2 arms), sponsored by Newave Pharmaceutical Inc. Primary endpoints: Maximum Tolerated Dose at 24 months, Recommended Phase 2 Dose at 24 months and 1 more. Started Jul 2021; status: recruiting.
02
Drugs
rocbrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Waldenstrom macroglobulinemia (WM)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04775745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04775745.